ArticleDiscover oncology2025
Induction chemotherapy followed by definitive chemoradiation in patients with inoperable esophageal squamous cell carcinoma: a multicenter retrospective study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEsophageal squamous cell carcinoma (ESCC) remains a global health challenge, characterized by significant geographic variations in incidence, risk factors, and treatment paradigms. While definitive chemoradiotherapy (CRT) is the cornerstone of therapy for inoperable locally advanced disease, the role of induction chemotherapy followed by CRT (CT-CRT) remains underexplored, particularly in Western populations. This study aimed to assess the survival outcomes of CRT and CT-CRT in a multicenter cohort with inoperable locally advanced ESCC.
methodsThis retrospective multicenter cohort study included 92 patients with inoperable stage II-IVA ESCC treated with CRT or CT-CRT between May 2015 and January 2024. Disease-free survival (DFS), overall survival (OS), distant metastasis-free survival (DMFS), response rates, and recurrence patterns were assessed and compared between CRT and CT-CRT groups.
resultsThe median age was 59 years, with a balanced gender distribution (52.2% male). The CT-CRT group exhibited significantly improved DMFS compared to CRT alone (HR: 0.363, 95% CI 0.154-0.857; p = 0.016). DFS and OS were similar in the CT-CRT group and CRT group, although there was a trend towards improved DFS and OS with CT-CRT (DFS: 16.9 vs. 11.4 months, p = 0.330; OS: 38.6 vs. 18.8 months, p = 0.209). In subgroup analysis, CT-CRT was associated with improved survival outcomes compared to CRT alone in advanced T stage (cT3-cT4) and TNM stage (III-IV).
conclusionInduction chemotherapy followed by CRT showed significantly improved DMFS and a trend towards improved DFS and OS in inoperable ESCC, particularly prominent in patients with more advanced T (T3-T4) or TNM (III-IV) stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.